These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. Laruelle M; van Dyck C; Abi-Dargham A; Zea-Ponce Y; Zoghbi SS; Charney DS; Baldwin RM; Hoffer PB; Kung HF; Innis RB J Nucl Med; 1994 May; 35(5):743-54. PubMed ID: 8176454 [TBL] [Abstract][Full Text] [Related]
7. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo. Larisch R; Schulte KW; Vosberg H; Ruzicka T; Müller-Gärtner HW J Nucl Med; 1998 Jun; 39(6):996-1001. PubMed ID: 9627332 [TBL] [Abstract][Full Text] [Related]
8. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197 [TBL] [Abstract][Full Text] [Related]
9. Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjects. Ichise M; Ballinger JR; Vines D; Tsai S; Kung HF J Nucl Med; 1997 Jan; 38(1):31-7. PubMed ID: 8998145 [TBL] [Abstract][Full Text] [Related]
10. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent. Kung MP; Kung HF; Billings J; Yang Y; Murphy RA; Alavi A J Nucl Med; 1990 May; 31(5):648-54. PubMed ID: 2140409 [TBL] [Abstract][Full Text] [Related]
11. 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia. Berding G; Gratz KF; Kolbe H; Meyer GJ; Dengler R; Knoop BO; Hundeshagen H Nuklearmedizin; 1994 Oct; 33(5):194-9. PubMed ID: 7997377 [TBL] [Abstract][Full Text] [Related]
12. Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis. Hierholzer J; Cordes M; Schelosky L; Richter W; Keske U; Venz S; Semmler W; Poewe W; Felix R J Nucl Med; 1994 Dec; 35(12):1921-7. PubMed ID: 7989970 [TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas. Bodei L; Hofland LJ; Ferone D; Mooy CM; Kros JM; Paridaens DA; Baarsma SG; Ferdeghini M; Van Hagen MP; Krenning EP; Kwekkeboom DJ Cancer Biother Radiopharm; 2003 Dec; 18(6):895-902. PubMed ID: 14969602 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of the three radioiodinated dopamine D2 receptor ligands [123I]IBF, [123I]epidepride and [123I]2'-ISP in nonhuman primates. Baldwin RM; Zea-Ponce Y; Zoghbi SS; al-Tikriti MS; Seibyl JP; Sybirska EH; Malison RT; Laruelle M; Charney DS; Hoffer PB Nucl Med Biol; 1994 Oct; 21(7):969-76. PubMed ID: 9234352 [TBL] [Abstract][Full Text] [Related]
15. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. Verhoeff NP; Kapucu O; Sokole-Busemann E; van Royen EA; Janssen AG J Nucl Med; 1993 Dec; 34(12):2076-84. PubMed ID: 8254390 [TBL] [Abstract][Full Text] [Related]
16. Limited sensitivity of iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl ] benzamide whole-body scintigraphy in patients with malignant melanoma: a comparison with thallium-201 imaging. Brenner W; Klomp HJ; Bohuslavizki KH; Szonn B; Kampen WU; Henze E Eur J Nucl Med; 1999 Dec; 26(12):1567-71. PubMed ID: 10638408 [TBL] [Abstract][Full Text] [Related]
17. [Phase 1 clinical study of 123I-IBF, a new radioligand for evaluating Dopamine D2 receptor with SPECT (II); pharmacokinetics study and quantification in the brain]. Yonekura Y; Sadato N; Tsuchida T; Uematsu H; Nakamura S; Onishi Y; Yamamoto K; Ishii Y Kaku Igaku; 1999 Feb; 36(2):155-68. PubMed ID: 10213983 [TBL] [Abstract][Full Text] [Related]
18. In vivo quantification of dopamine D2 receptor parameters in nonhuman primates with [123I]iodobenzofuran and single photon emission computerized tomography. Laruelle M; al-Tikriti MS; Zea-Ponce Y; Zoghbi SS; Baldwin RM; Charney DS; Hoffer PB; Kung HF; Innis RB Eur J Pharmacol; 1994 Sep; 263(1-2):39-51. PubMed ID: 7821360 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders]. Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375 [TBL] [Abstract][Full Text] [Related]